CytRx Corp. (NASDAQ:CYTR) announced last week that it formedVaxcel Inc., a wholly owned subsidiary that will develop andcommercialize new vaccine adjuvant systems.
CytRx of Norcross Ga., will transfer to Vaxcel the rights to itsimmunoadjuvant TiterMax, which is already on the market forresearch applications.
CytRx is developing therapeutics incorporating its copolymers.In critical care therapies, its products address treating vascularand infectious diseases, cancer and burns.
(c) 1997 American Health Consultants. All rights reserved.